Liver-disease company: owns FibroScan liver-stiffness scanners through French unit Echosens and sells the liver-fibrosis drug Fufang Biejia Ruangan.
Liver-disease company: owns FibroScan liver-stiffness scanners through French unit Echosens and sells the liver-fibrosis drug Fufang Biejia Ruangan.
Pairs a diagnostic with a treatment in one disease area: FibroScan scanners, made by its French unit Echosens, are sold to hospitals and clinics for non-invasive liver testing, and a protected traditional Chinese medicine for liver fibrosis is sold through pharmaceutical distributors. Echosens sells in China and overseas and holds the core elastography patents.
Moat: narrow (IP / patents, installed base). Pioneer of transient elastography with a large installed base; the drug is a nationally protected Chinese patent medicine.
Headquarters: Beijing, China · Founded: 2001 · Employees: 964
Size Inner Mongolia Furui Medical Science (300049.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.45B, the 1557th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥39.00 on 18 Nov 2026.
Performance Over six months the shares fell 31.5%, against -1.8% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 11.3% over the last twelve months (peer median +13.3%); the operating margin is 25.5% (peer median 6.8%).
Valuation It trades at 41.9× forward earnings against a peer median of 25.1× (4th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.64B | CN¥1.59B | CN¥1.35B | CN¥1.14B | CN¥998M |
| Revenue growth | — | +18% | +18% | +15% | — |
| Gross profit | CN¥1.24B | CN¥1.09B | CN¥931M | CN¥813M | CN¥698M |
| EBITDA | n/a | CN¥505M | CN¥380M | CN¥335M | CN¥255M |
| Net income | CN¥176M | CN¥154M | CN¥113M | CN¥102M | CN¥97.9M |
| Free cash flow | CN¥247M | CN¥165M | CN¥5.12M | CN¥121M | CN¥105M |
| Capital expenditure | CN¥164M | CN¥189M | CN¥219M | CN¥189M | CN¥90.8M |
| Total debt | CN¥254M | CN¥137M | CN¥83.4M | CN¥59.3M | CN¥55.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Inner Mongolia Furui Medical Science 300049.SZ | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% |
| Siemens Healthineers SHL.DE | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% |
| GE HealthCare GEHC | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300049.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.8% | -0.1% | 9th lowest of 21 |
| 6-month return | -31.5% | -1.8% | 3rd lowest of 21 |
| Distance from 52-week high | -55.1% | -26.7% | 3rd lowest of 21 |
| Revenue growth (TTM) | +11.3% | +13.3% | 11th highest of 21 |
| Operating margin | 25.5% | 6.8% | 5th highest of 21 |
| Forward P/E | 41.9× | 25.1× | 4th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 2.9% | 18.4% | 3rd least demanding of 15 |
| Growth delivered (Del g) | +14.6% | +17.4% | 7th lowest of 15 |
| Hurdle (Req g minus delivered) | -11.7 pp | -3.8 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | +9.6 pp | -1.1 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |